Post-ROSC Sedation Management for Unconscious Patients with Spontaneous Breathing

Sedation Strategy

The American Heart Association recommends using titrated, light-to-moderate sedation with short-acting agents to maintain patient comfort and ventilator synchrony, while avoiding deep sedation that could delay neurological assessment and worsen outcomes 1, 2
The European Heart Journal suggests starting with low-dose opioid analgesia as the foundation of sedation, and adding short-acting sedatives only if analgesia alone is insufficient to control agitation or achieve ventilator synchrony 3
The European Heart Journal recommends using preferred sedative agents such as propofol, dexmedetomidine, and remifentanil, with specific dosing guidelines for each agent 2, 3

The European Heart Journal advises against using midazolam for prolonged use due to its active metabolite accumulation in renal dysfunction, deliriogenic effects, and delayed awakening 3
The European Heart Journal also advises against using lorazepam for prolonged use due to its long duration, deliriogenic effects, and propylene glycol toxicity at high doses 3
The American Heart Association recommends monitoring sedation depth using validated scales, such as the RASS, and considering bispectral index (BIS) monitoring during neuromuscular blockade 1, 2, 4

The American Heart Association recommends avoiding or minimizing neuromuscular blocking agents, using them only for short intervals when patient agitation is life-threatening and adequate sedation has failed 1, 2
The American Heart Association advises providing adequate sedation before and during neuromuscular blockade, monitoring depth of blockade, and exercising extreme caution in patients at high risk of seizures 1, 2

The European Heart Journal notes that oversedation can delay neurological prognostication, mask seizure activity, and prolong mechanical ventilation 3, 5
The American Heart Association warns that undersedation can lead to patient-ventilator dyssynchrony, agitation and delirium, and shivering during targeted temperature management 1, 4, 5

The 2010 American Heart Association guidelines state that there is little evidence to guide sedation/analgesia therapy immediately after ROSC, with a Class IIb, Level of Evidence C recommendation 1, 2
The 2023 European Heart Journal guidance provides a detailed algorithmic approach to sedation management, particularly for patients undergoing targeted temperature management 3